CRISPR Therapeutics AG

NasdaqGM:CRSP Stock Report

Market Cap: US$5.6b

CRISPR Therapeutics Valuation

Is CRSP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRSP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRSP ($68.16) is trading below our estimate of fair value ($73.09)

Significantly Below Fair Value: CRSP is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRSP?

Other financial metrics that can be useful for relative valuation.

CRSP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.2x
Enterprise Value/EBITDA-20.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CRSP's PS Ratio compare to its peers?

The above table shows the PS ratio for CRSP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average15.2x
BPMC Blueprint Medicines
23.3x28.0%US$5.8b
IONS Ionis Pharmaceuticals
8x17.9%US$6.5b
APLS Apellis Pharmaceuticals
17.9x27.2%US$7.1b
ABCM Abcam
11.6x13.0%US$5.5b
CRSP CRISPR Therapeutics
14.7x37.8%US$5.6b

Price-To-Sales vs Peers: CRSP is good value based on its Price-To-Sales Ratio (14.7x) compared to the peer average (15.2x).


Price to Earnings Ratio vs Industry

How does CRSP's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: CRSP is expensive based on its Price-To-Sales Ratio (14.7x) compared to the US Biotechs industry average (14.4x).


Price to Sales Ratio vs Fair Ratio

What is CRSP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRSP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.7x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: CRSP is expensive based on its Price-To-Sales Ratio (14.7x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRSP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$68.16
US$88.08
+29.2%
39.0%US$199.00US$30.00n/a24
Mar ’25US$83.75
US$87.29
+4.2%
39.3%US$199.00US$30.00n/a24
Feb ’25US$64.67
US$86.92
+34.4%
44.1%US$199.00US$30.00n/a24
Jan ’25US$62.60
US$85.66
+36.8%
43.3%US$188.00US$30.00n/a25
Dec ’24US$68.65
US$88.36
+28.7%
48.7%US$220.00US$42.00n/a24
Nov ’24US$43.75
US$88.69
+102.7%
48.1%US$220.00US$43.00n/a24
Oct ’24US$45.39
US$86.38
+90.3%
45.0%US$220.00US$43.00n/a25
Sep ’24US$50.53
US$86.60
+71.4%
48.0%US$220.00US$43.00n/a26
Aug ’24US$56.41
US$84.95
+50.6%
45.2%US$220.00US$42.00n/a27
Jul ’24US$56.14
US$84.76
+51.0%
45.5%US$220.00US$42.00n/a27
Jun ’24US$64.52
US$84.67
+31.2%
45.4%US$220.00US$42.00n/a27
May ’24US$49.08
US$85.40
+74.0%
46.9%US$220.00US$39.00n/a25
Apr ’24US$45.23
US$86.68
+91.6%
46.3%US$220.00US$39.00n/a25
Mar ’24US$47.72
US$91.52
+91.8%
43.7%US$220.00US$39.00US$83.7523
Feb ’24US$52.33
US$97.00
+85.4%
42.4%US$220.00US$37.00US$64.6723
Jan ’24US$40.65
US$100.27
+146.7%
40.4%US$220.00US$37.00US$62.6022
Dec ’23US$54.34
US$104.71
+92.7%
39.6%US$220.00US$37.00US$68.6524
Nov ’23US$52.02
US$110.71
+112.8%
37.3%US$220.00US$37.00US$43.7524
Oct ’23US$65.35
US$115.30
+76.4%
33.2%US$220.00US$50.00US$45.3923
Sep ’23US$65.60
US$115.30
+75.8%
33.2%US$220.00US$50.00US$50.5323
Aug ’23US$74.01
US$115.30
+55.8%
36.5%US$220.00US$46.00US$56.4123
Jul ’23US$63.79
US$115.30
+80.8%
36.5%US$220.00US$46.00US$56.1423
Jun ’23US$57.87
US$117.41
+102.9%
37.0%US$220.00US$46.00US$64.5222
May ’23US$49.62
US$133.05
+168.1%
30.7%US$220.00US$64.00US$49.0822
Apr ’23US$66.15
US$136.50
+106.3%
29.9%US$220.00US$64.00US$45.2320
Mar ’23US$57.44
US$137.80
+139.9%
28.2%US$220.00US$64.00US$47.7220

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.